BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 14.07.2009

Dual Antiplatelet Therapy Trial: Research Project Grant (R01)

The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of the Office of Critical Path Programs (OCPP). The goal of the Dual Antiplatelet Therapy (DAPT) Trial is to solicit a sole source grant application from Harvard Clinical Research Institute (HCRI) that proposes to provide funding in support of a dual antiplatelet therapy clinical trial being conducted by HCRI.

Source: Federal Register — Food and Drug AdministrationOpen original release →